The record
Every action on file
87 regulatory or legal actions against 75 of the 107 providers on this site. Each links to the primary document — an FDA letter, a court filing, a regulator’s own announcement. Nothing here is sourced from a blog.
- Actions on file
- 87
- Companies involved
- 75 of 107
- Most recent
- July 2026
- Busiest month
- 26 in February 2026
By date
The timeline
Newest first, grouped by the month the action was published or filed.
July 2026 3 actions
Hims — The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven.
Hers — The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven. Hers is the same legal entity.
Willow — Reopened NAD matter closed after Willow Health Services voluntarily discontinued claims that its compounded semaglutide was proven to support weight loss, delivered results comparable to FDA-approved semaglutide, and produced effective weight loss without diet or exercise.
June 2026 25 actions
Altru Telehealth — FDA warning letter to Altru Telehealth, LLC alleging its website described compounded semaglutide and tirzepatide as having "FDA-approved active ingredients" and offering "the same results" as branded drugs, and described compounding pharmacies as "FDA approved" and "FDA licensed", which misbranded the products.
altRx — FDA warning letter to Trinity HealthCare Supply, LLC dba altRx alleging its website labelling identified "altRx" on pictured compounded semaglutide and tirzepatide labels, suggesting altRx was the compounder when it was not, and that claims such as "clinically proven weight loss" represented the compounded products as FDA-approved or evaluated for safety and effectiveness.
AM Rx — FDA warning letter to FitRX, LLC dba AM RX alleging its compounded product labels bore "AM Rx" as though it were the manufacturer, and that describing the compounded drugs as containing "the active ingredient in FDA-approved medications like Wegovy and Ozempic" misrepresented them as FDA-approved.
Amie — FDA warning letter to Amie Health, Inc. dba Amie alleging its website made false or misleading claims about compounded semaglutide and tirzepatide, including "All our treatments use FDA-approved active ingredients", and that product labels displaying "amie" suggested Amie was the compounder when it was not.
Clover Meds — FDA warning letter to Clover Meds LLC alleging its compounded semaglutide and tirzepatide were misbranded because the labels carried the "Clover Meds" name, suggesting it was the manufacturer, and because its website described products as coming from "FDA-licensed Facilities".
D&H Medical Center — FDA warning letter to D&H Medical Services alleging that marketing its compounded products as the "Same ingredient as Ozempic", "Same ingredient as Rybelsus" and "Same ingredient as Mounjaro" represented them as FDA-approved or evaluated for safety and effectiveness when they were not.
DrMedHealth — FDA warning letter to Public Health Solution LLC dba DrMedHealth alleging that website claims describing its compounded products as having the "Same active ingredient as Ozempic" and "Same active ingredient as Mounjaro" misrepresented compounded drugs as FDA-approved or evaluated for safety and effectiveness.
Eden — FDA warning letter to Eden Health International, Inc. dba Eden (MARCS-CMS 728279).
Ezra — FDA warning letter to Ezra Holdco LLC dba Ezra alleging its website labelling for compounded semaglutide and tirzepatide identified "Ezra" on the pictured label, suggesting Ezra was the compounder of those drugs when it was not.
Fitish — FDA warning letter to FITISH alleging that "FITISH" appearing on compounded product labels suggested it was the manufacturer, and that statements such as "Semaglutide is the active ingredient in ozempic" and "Tirzepatide is the active ingredient in Mounjaro and Zepbound" misrepresented the compounded drugs as FDA-approved.
Harper Meds — FDA warning letter to Nexus Health Solutions LLC dba Harper Meds alleging that "Harper Meds" on compounded product labels suggested it was the manufacturer, that the claim "Same active ingredient as Ozempic & Wegovy" implied FDA approval, and that describing its sources as "FDA-licensed 503A Outsourcing Facilities" was false because compounding facilities are not FDA-licensed.
HydraMed — FDA warning letter to HydraMed IV LLC dba HydraMed alleging that "HydraMed" on compounded semaglutide and tirzepatide labels suggested it was the manufacturer, and that its website claim that products came from an "FDA-approved pharmacy" was false because compounding pharmacies and outsourcing facilities are not FDA-approved or FDA-licensed.
Joi + Blokes — FDA warning letter to Joi and Blokes alleging it misbranded compounded semaglutide and tirzepatide by presenting them as equivalent to FDA-approved products such as Ozempic and Wegovy, and by displaying the Joi + Blokes name on labels of drugs it did not compound.
Maximus — FDA warning letter to Maximus Health, Inc. dba Maximus alleging its website made false or misleading claims about compounded semaglutide and tirzepatide, including "Proven to lose weight effectively" and references to "FDA approved pharmacies" that represented the compounded products as FDA-approved or evaluated for safety and effectiveness.
Medica Weight Loss — FDA warning letter to Medica Weight Loss alleging it misbranded compounded semaglutide and tirzepatide by implying FDA approval, describing its compounding source as an "FDA-approved pharmacy", and putting its own branding on labels of drugs it did not compound.
Mint Med — FDA warning letter to Glow Medispa, LLC dba Mint Med alleging its website labelling identified "Mint Med" on pictured compounded semaglutide and tirzepatide labels, suggesting Mint Med was the compounder of those drugs when it was not.
Momentum Health — FDA warning letter to Momentum Health 360 dba Momentum Health alleging its website labelling identified "Momentum Health" on pictured compounded semaglutide, tirzepatide and liraglutide labels, suggesting it was the compounder when it was not, and that claims including "Same active ingredient in Mounjaro and Zepbound" and describing compounding facilities as "FDA-licensed" were false or misleading.
NativeMed — FDA warning letter to NativeMed LLC alleging it misbranded compounded tirzepatide by displaying its own logo on labels of drugs it did not compound, and marketed compounded semaglutide as containing "The same active ingredient in Ozempic and Wegovy", implying FDA approval it does not have.
Nexlife — FDA warning letter to Nexlife Inc. dba Nexlife alleging its website labelling identified "Nexlife" on pictured compounded semaglutide and tirzepatide labels, suggesting Nexlife was the compounder of those drugs when it was not, and that its representations about the products were false or misleading.
NOVARX — FDA warning letter to Nova Vascular LLC dba NOVARX alleging it misbranded compounded semaglutide and tirzepatide by advertising "access to the same active ingredient found in Ozempic", claiming products came from "FDA Approved Pharmacies", and displaying "NOVA RX" on labels of drugs it did not compound.
OrderlyMeds — FDA warning letter to OrderlyMeds LLC dba OrderlyMeds (MARCS-CMS 728291), part of the June 2026 round over compounded GLP-1 marketing.
Ready Med — FDA warning letter to Ready Med alleging it misbranded compounded semaglutide and tirzepatide by marketing them as "The same active ingredient in Mounjaro and Zepbound" and "The same active ingredient in Ozempic and Rybelsus", claiming they came from an "FDA licensed compounding facility", and displaying "Ready Med" on labels of drugs it did not compound.
RoenRx — FDA warning letter to Roen Health, Inc. dba RoenRx alleging it misbranded compounded semaglutide by displaying "RoenRx" on labels of a drug it did not compound, and by stating that "Semaglutide is the active ingredient in FDA-approved medications like Wegovy and Ozempic", which the agency said implies FDA approval the compounded product lacks.
Thrivelab — FDA warning letter to Thrivelab Co. dba Thrivelab alleging its website labelling identified "thrivelab" on pictured compounded semaglutide labels, suggesting Thrivelab was the compounder when it was not, and that claims such as "Same active ingredient as Wegovy and Ozempic" and "clinically proven to work" represented the compounded product as FDA-approved or evaluated for safety and effectiveness.
VivioMD — FDA warning letter to VivioMD Group LLC alleging it misbranded compounded semaglutide and tirzepatide because the product labels pictured on its website identify "VivioMD" as the compounder when it is not, and that the products are unapproved new drugs.
May 2026 2 actions
Noom (Noom Med) — NAD (BBB National Programs) decision, challenged by Eli Lilly, recommended Noom discontinue or modify its 'Microdose GLP-1Rx' claims for lack of support that the lower dose delivers a measurable health benefit; Noom disagreed but agreed to comply.
AgelessRx — AgelessRx filed a notice with the California Attorney General reporting that between 17 and 22 April 2026 an unauthorised party accessed help-desk tickets containing customer names together with date of birth, health diagnosis or condition, medications and other treatment information, and offered twelve months of Experian credit monitoring in response. This is a breach the company disclosed about itself, not an enforcement action against it.
April 2026 1 action
Zealthy — DOJ/FTC filed an amended complaint seeking an immediate asset freeze and receivership against Zealthy and CEO Kyle Robertson, alleging foreign call-centre contractors and unlicensed non-clinicians ordering prescriptions, doctors' names and NPIs used without their knowledge, unauthorised card charges while cancellation attempts were blocked, and misuse of patients' health information for social media marketing; Zealthy also lost its LegitScript certification in 2025.
March 2026 2 actions
Hims — Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.
Hers — Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.
February 2026 26 actions
Willow — Eli Lilly sued Willow Health Services, Inc. in the Central District of California on 23 April 2025 (No. 2:25-cv-03570) over compounded tirzepatide. The case was dismissed with prejudice on 3 February 2026 for failure to establish Lanham Act standing — the court held the prescribing physician, not Willow's advertising, was the proximate cause of any lost sales — with no ruling on whether the marketing was misleading. Lilly has appealed to the Ninth Circuit (No. 26-1317).
24hrdoc — FDA warning letter to 24HrDoc, Inc. alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the 24HrDoc name, representing it as the manufacturer when it was not, and because website claims such as "Same ingredients as: Ozempic and Wegovy" implied the products were FDA-approved.
Alan — FDA warning letter to Alan Health Technologies Inc. alleging it misbranded compounded semaglutide and tirzepatide, stating that the representations on its website that Alan is the compounder of these drug products are false or misleading, and that the products appear not to meet the conditions for compounded-drug exemptions under sections 503A or 503B.
Belle — FDA warning letter to Belle Health LLC alleging it misbranded compounded semaglutide and tirzepatide because, in the letter's words, the products displayed on its website identify "Belle" on the pictured label, suggesting Belle is the compounder of those drugs when in fact it is not.
Bliv — FDA warning letter to Bliv Wellness LLC alleging that the compounded semaglutide and tirzepatide products shown on its website display "Bliv" on the pictured label, suggesting Bliv is the compounder of those drugs when in fact it is not, making the representations false or misleading and the products misbranded.
BluefitMD — FDA warning letter to BluefitMD alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the BluefitMD name, representing it as the compounder when it was not, and because website claims such as "Compounded Semaglutide (the same active ingredient as Ozempic and Wegovy)" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.
Fifty 410 — FDA warning letter to Aspen Aesthetics dba Fifty 410 alleging that the compounded semaglutide and tirzepatide products on its website identify "Fifty 410" on the pictured label, suggesting Fifty 410 is the compounder when it is not, and that its "clinically proven ingredients" claim implies the products were FDA-approved or evaluated for safety and effectiveness when they were not.
FitRx — FDA warning letter to FitRX, LLC dba FitRx alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the FitRx name, representing it as the compounder when it was not, and because website claims such as "semaglutide (active ingredient in Wegovy)" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.
Genesis Health — FDA warning letter to Genesis Health International Inc. alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the Genesis name, representing it as the manufacturer when it was not, and because website claims such as "Contains the same active ingredient as Ozempic and Wegovy" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.
GoodGirlRX — FDA warning letter to Good Girl LLC dba GoodGirlRX alleging it misbranded compounded semaglutide and tirzepatide by displaying "GoodGirlRX" on the pictured labels, suggesting it was the compounder when it was not, and by website statements including "FDA-approved meds" and "Clinically proven GLP-1 results", which the agency said imply FDA approval the compounded products do not have.
Ivím Health — FDA warning letter to Ivim Services LLC dba Ivim (MARCS-CMS 721816), part of the February 2026 telehealth action over compounded GLP-1 marketing.
Join Josie — FDA warning letter to Join Josie alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the Join Josie name, representing it as the sole manufacturer when it was not, and because claims such as "The same active ingredient found in the FDA-approved brand Wegovy" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.
Kin Meds — FDA warning letter to Kin Meds alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the Kin Meds name, representing it as the manufacturer when it was not, and because claims such as "Same Active Ingredient as common brands" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.
Levity — FDA warning letter to Levity Inc. alleging it misbranded compounded semaglutide and liraglutide by displaying "Levity" on the pictured labels, suggesting Levity was the compounder when it was not, and by website claims such as "The same ingredient as Ozempic + Wegovy" and "The power of Saxenda" that the agency said imply FDA approval the compounded products do not have.
Measured — FDA warning letter to Better Health Labs, Inc. dba Measured alleging it misbranded compounded semaglutide and tirzepatide by displaying "Measured" on the pictured labels, suggesting Measured was the compounder when it was not, and by advertising products with "the same active ingredients found in Wegovy, Ozempic, Zepbound, and Mounjaro", which the agency said implies FDA approval the compounded products do not have.
MEDVi — FDA warning letter to MEDVi, LLC dba MEDVi (MARCS-CMS 721455) alleging the products carried MEDVi branding that falsely suggested MEDVi was the compounder, that claims such as 'same active ingredient as Wegovy and Ozempic' implied FDA approval, and that the products were misbranded under FD&C Act sections 502(a) and 502(bb), with seizure, injunction and border detention warned as possible consequences.
NewSelf — FDA warning letter to NewSelf Limited alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the NewSelf name, representing it as the manufacturer when it was not, and because website claims such as "Same active ingredient as Ozempic & Wegovy" and references to "FDA-approved use" implied the compounded products had been FDA-approved.
Peaks — FDA warning letter to Peaks Curative, LLC alleging it misbranded compounded semaglutide by displaying "Peak Now" on the pictured label, suggesting it was the compounder when it was not, and by website statements including "This FDA-approved treatment promotes safe, effective weight loss" and "Clinically proven to aid in significant weight loss", which the agency said imply FDA approval the compounded products do not have.
PharmaZee — FDA warning letter to PharmaZee alleging its website's compounded semaglutide and tirzepatide labels displayed the PharmaZee name, suggesting PharmaZee is the compounder when it is not, and that claims such as "clinically proven medications" and "Same active ingredient as Ozempic and Wegovy" imply the products were FDA-approved or evaluated for safety and effectiveness when they were not.
Premium Health — FDA warning letter to Premium Health Management Inc. alleging its website's compounded semaglutide and tirzepatide labelling identified Premium Health as the compounder when it is not, and that website claims referencing Ozempic, Wegovy and Mounjaro and describing the products as "generic compounded medication" imply FDA approval or evaluation that has not occurred.
Refills — FDA warning letter to Refills Health, LLC alleging its website's compounded semaglutide labelling displayed the Refills Health name, suggesting it is the compounder when it is not, and that claims including "clinically proven" and "the same active ingredient found in certain FDA approved treatments" imply the products were FDA-approved or evaluated for safety and effectiveness when they were not.
SkinnyRx — FDA warning letter to Lean Rx, Inc. dba SkinnyRx alleging it misbranded compounded semaglutide and tirzepatide by displaying "SkinnyRx" on the pictured labels, suggesting SkinnyRx was the compounder when it was not, and by website statements including "Get access to the same active ingredient as name-brand GLP-1 medications" and "It contains the same active ingredient as FDA-approved medications", which the agency said imply FDA approval the compounded products do not have.
Strut Health — FDA warning letter to Strut Health, LLC dba Strut (MARCS-CMS 721448).
Thrive Health Solutions — FDA warning letter to Thrive Health and Wellness, LLC dba Thrive Health Solutions alleging its sterile drug products, including NAD+ injection and MEGALean tirzepatide injections, were prepared, packed or held under insanitary conditions — citing aseptic operations conducted outside a certified ISO 5 area, personnel who had never performed media fills, non-sterile gloves with exposed hair and skin, carpeted flooring and failure to use a sporicidal agent — and that the products are unapproved new drugs and misbranded for lacking adequate directions for use.
WeightCare — FDA warning letter to Weightless Medical LLC dba WeightCare alleging it misbranded compounded semaglutide and tirzepatide, stating that the representations on its website that WeightCare is the compounder of these drug products are false or misleading, and that the misbranded products were introduced into interstate commerce.
Zeuss — FDA warning letter to Zeuss LLC alleging its compounded tirzepatide was misbranded because the label bore the Zeuss name, representing it as the compounder when it was not, and because website statements including "It is FDA approved and clinically proven to work treatment for weight loss" implied FDA approval the compounded product does not have.
December 2025 1 action
Willow — The National Advertising Division, on a challenge by Novo Nordisk, recommended on 4 December 2025 that Willow Health Services discontinue or modify health claims for its compounded semaglutide products. Willow declined to provide a compliance statement, and NAD referred the matter to regulatory authorities and to the platforms carrying the advertising.
September 2025 19 actions
Hims — FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing.
Hers — FDA warning letter to Hims & Hers Health, Inc. dba Hers (MARCS-CMS 716825) over compounded GLP-1 marketing.
Bioverse — FDA warning letter to Bioverse, Inc. alleging claims that its compounded products contained "the same active ingredient as Ozempic and Wegovy" or "Mounjaro and Zepbound" implied they were the same as FDA-approved products, making them misbranded.
Curex — FDA warning letter to Curex alleging its marketing of compounded semaglutide and tirzepatide — including "clinically proven success" and "the same active ingredients as Ozempic or Mounjaro" — implied its products were the same as FDA-approved drugs, making them misbranded.
DirectMeds — FDA warning letter to directmeds.com, Inc. alleging its compounded semaglutide and tirzepatide were misbranded because claims that the products "contain the same active ingredient as branded" medications and are an "effective and budget-friendly alternative" implied equivalence to FDA-approved drugs.
Elevated Health — FDA warning letter to Elevate Your Wellness LLC dba Elevated alleging its compounded semaglutide and tirzepatide were misbranded because claims that they "contain the same active ingredient as the branded medications" implied equivalence to FDA-approved drugs.
Fancy Meds — FDA warning letter to Fancy Meds, LLC alleging its compounded semaglutide and tirzepatide were misbranded because website claims that the products contained "the same active ingredient as" Ozempic, Wegovy, Mounjaro and Zepbound implied equivalence to FDA-approved drugs.
FWD — FDA warning letter to FWD Care, Inc. alleging claims such as "Same active ingredient in Mounjaro and Zepbound" for its compounded semaglutide and tirzepatide implied its products were the same as FDA-approved drugs, making them misbranded.
Healthon — FDA warning letter to Healthon Inc. alleging claims such as "Same active ingredient as Wegovy and Ozempic" and "Clinically proven weight loss" implied its compounded semaglutide and tirzepatide were the same as FDA-approved products, making them misbranded.
Healthy Male — FDA warning letter to Healthy Male alleging its compounded tirzepatide was misbranded because claims including "Clinically shown to support 15-22% average body weight reduction" and "Clinically proven to deliver sustainable results" implied the compounded product was the same as an FDA-approved product.
JulyMD — FDA warning letter to JulyMD alleging claims that its compounded semaglutide had "the same active ingredient as Wegovy and Ozempic" and offered "the same effective ingredient but at a fraction of the price" implied its product was the same as an FDA-approved drug, making it misbranded.
LillyDirect — FDA warning letter to Eli Lilly and Company (MARCS-CMS 716485) finding that the company's participation in an ABC primetime special created a misleading impression regarding the safety of Zepbound and Mounjaro, and misbranded those drugs.
LumiMeds — FDA warning letter to Lumimeds alleging claims that its compounded products contained "the same active ingredient as the brand name medications" and that "GLP-1 was FDA-approved in 2017" implied its unapproved compounded drugs were the same as FDA-approved products, making them misbranded.
NovoCare Pharmacy — FDA warning letter to Novo Nordisk, Inc. (MARCS-CMS 716495) finding that the same ABC primetime special minimised and omitted risk information, creating a misleading impression regarding the safety of Wegovy, Ozempic and Victoza.
Remedy Meds — FDA warning letter to Remedy Meds alleging website claims such as "Semaglutide (Compounded) Same active ingredient as Ozempic and Wegovy" and "Tirzepatide (Compounded) Same active ingredient as Mounjaro and Zepbound" implied its compounded products were the same as FDA-approved drugs, making them misbranded.
Sprout Health — FDA warning letter to Sprout Health Partners LLC alleging its compounded semaglutide and tirzepatide marketing was false or misleading — citing the claim that "GLP-1 medications are FDA-approved and backed by extensive clinical research" — making the products misbranded.
TRYM Health — FDA warning letter to TRYM Health, Inc. alleging website claims including "Clinically Proven to Work", "Contains the same active ingredient as Mounjaro and ZepBound" and "Contains the same active ingredient as Ozempic and Wegovy" implied its compounded products were the same as FDA-approved drugs, making them misbranded.
Tuyo Health — FDA warning letter to Tuyo Health, Inc. alleging its compounded semaglutide and tirzepatide were misbranded because website claims such as "Same active as Wegovy and Ozempic" and "Same active ingredient as Zepbound and Mounjaro" implied equivalence to FDA-approved drugs.
Villas Health — FDA warning letter to Las Villas Health Care LLC dba Villas Health alleging its compounded semaglutide and compounded sildenafil were misbranded because claims that the semaglutide "contains the same active ingredient as Ozempic and Wegovy" and that the sildenafil was "the active ingredient in Viagra" with clinical proof for female sexual arousal disorder implied equivalence to FDA-approved drugs.
August 2025 1 action
Mochi Health — Novo Nordisk sued Mochi Health Corp. and its affiliated medical practices in the Northern District of California on 4 August 2025 (No. 5:25-cv-06563), alleging false advertising and unlawful mass compounding of semaglutide, including converting standard doses to non-standard ones and adding vitamin B12; allegations unproven.
June 2025 1 action
Hims — Consolidated securities class action, In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.), first filed 25 June 2025, alleging misrepresentations about the company's business and its Novo Nordisk relationship; disclosed by the company in its Form 10-Q for the quarter ended 30 June 2026. Allegations unproven.
April 2025 2 actions
Mochi Health — Eli Lilly sued Mochi Health Corp. in the Northern District of California on 23 April 2025 (No. 3:25-cv-03534) over compounded tirzepatide combined with additives including niacinamide, pyridoxine and glycine. In October 2025 the court granted Mochi's motion to dismiss with leave to amend, holding Lilly had not established standing on reputational harm alone.
Henry Meds — Eli Lilly sued Adonis Health, Inc. d/b/a Henry Meds in the Northern District of California on 23 April 2025 (No. 4:25-cv-03536) over its marketing of compounded tirzepatide against Mounjaro and Zepbound. In September 2025 the court dismissed Lilly's safety and efficacy claims and allowed its personalisation claims to proceed.
March 2025 1 action
Mochi Health — The Washington State Pharmacy Quality Assurance Commission issued a Limited Stop Service order on 13 March 2025 against Aequita Pharmacy LLC of Kirkland, Washington — reported to compound for Mochi Health — barring it from compounding or dispensing compounded products in the state, citing untrained and unqualified staff performing sterile compounding, inadequate supervision, and failure to follow sterile compounding procedures.
May 2024 1 action
Zealthy — The United States, on referral from the FTC, sued Cerebral, Inc., Zealthy, Inc., Gronk, Inc. and chief executive Kyle Robertson in the Southern District of Florida (No. 1:24-cv-21376); the first amended complaint of 31 May 2024 alleges deceptive cancellation practices and mishandling of consumers' health data. Allegations unproven.
April 2024 1 action
Zealthy — Zealthy CEO Kyle Robertson is the founding CEO of Cerebral, which settled FTC/DOJ charges over data sharing and deceptive cancellation practices.
July 2022 1 action
Noom (Noom Med) — Nichols et al. v. Noom Inc., No. 1:20-cv-03677 (S.D.N.Y.) — a consolidated class action over auto-enrolment and auto-renewal practices, in which Geraldine Mahood was a named plaintiff — received final approval on 12 July 2022 of a settlement establishing a $56 million gross settlement fund plus reforms to Noom's enrolment and cancellation practices.
By provider
Who has the most on record
The eight companies with the largest files. Every provider with anything on record is marked in the table on the front page.
Why so much of this happened at once
Between September 2025 and March 2026 the FDA issued roughly 85 warning letters to telehealth companies selling compounded GLP-1s. The objection was rarely the compounding itself, which is legal. It was the marketing: describing a compounded drug as a generic version of, or the same as, an approved one; implying FDA approval; or advertising the drug under the telehealth company’s own brand without saying where it came from.
In February 2026 the agency went further and moved to restrict the active ingredients used in non-approved compounded GLP-1 products. That is why several companies on this site now supply FDA-approved medication when a year ago they did not — and why a price you saw quoted in 2025 may not exist any more.
Straight answers
What the record does and does not say
- Which GLP-1 telehealth companies have FDA warning letters or lawsuits against them?
- 75 of the 107 providers on this site have at least one sourced action on record, 87 in total. They are listed by provider above, and each action links to the document it came from.
- Why has the FDA been sending warning letters about compounded GLP-1s?
- Largely over marketing claims rather than the compounding itself. The FDA prohibits telehealth companies from describing a compounded drug as a generic version of, or the same as, an FDA-approved drug; from claiming it has been FDA-approved or evaluated for safety and effectiveness; and from implying it comes from an FDA-approved pharmacy, because the FDA does not approve or license compounding facilities. Roughly 85 warning letters went out between September 2025 and March 2026.
- Does a company with an action against it still operate?
- Almost all of them do. A warning letter is a demand to correct something, not a shutdown order, and several companies here responded by changing what they sell rather than by closing. That is precisely why a page saying only “this company got a letter” is worse than useless — what matters is what the letter said and what happened next.
- How do I check any of this myself?
- Follow the “Primary source” link under each entry. Every one goes to the document itself — an FDA warning letter on fda.gov, a court filing, a regulator's own announcement. If a claim on this site has no such link, it should not be here; tell us and we will remove it.